Last Price$94.70.7%
Market Cap$240.5B
LTM Net Debt to Free Cash Flow
(0.9x)
5Y avg
2.2x
Drug Manufacturers - General industry
median
1.3x
Stock quality & Intrinsic value
7/10
0.3% undervalued
Merck & Co., Inc. Net Debt to Free Cash Flow
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Debt to Free Cash Flow | (0.0x) | (1.2x) | (0.3x) | (0.4x) | 0.1x | 4.1x | 0.6x | 0.2x | 0.5x | 0.7x | 1.0x | 1.2x | 1.2x | 3.5x | 2.0x | 1.7x | 4.6x | 2.7x | 1.3x | 3.2x |
Overvalued or undervalued?
Check the intrinsic value for MRK
and see if it's the right time to invest.
Merck & Co., Inc. (MRK) Net Debt to Free Cash Flow comparison analysis
General
LTM Net Debt to Free Cash Flow
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Merck & Co., Inc.MRK
(0.9x)
1.4%
(97.6%)
0.6%
Median Peer Set
2.1x
8.0%
(5.7%)
12.6%
Eli Lilly and CompanyLLY
16.3x
32.0%
102.4%
23.5%
Amgen Inc.AMGN
4.6x
18.6%
(39.8%)
12.2%
AbbVie Inc.ABBV
3.5x
3.7%
(11.4%)
7.6%
AstraZeneca PLCAZN
3.4x
18.0%
135.9%
13.0%
Bristol-Myers Squibb CompanyBMY
2.9x
7.3%
N/A
(18.5%)
Novartis AGNVS
1.3x
10.8%
(16.5%)
23.1%
Johnson & JohnsonJNJ
0.7x
4.3%
(57.9%)
15.8%
Gilead Sciences, Inc.GILD
(1.0x)
6.0%
(91.6%)
1.7%
Pfizer Inc.PFE
(2.5x)
8.8%
273.7%
12.6%
SanofiSNY
(19.8x)
(3.8%)
3.1%
12.6%
MRK key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 22,938.6 0.0% | 22,011.9 (4.0%) | 22,636.0 2.8% | 24,197.7 6.9% | 23,850.3 (1.4%) | 27,428.3 15.0% | 45,987.0 67.7% | 48,047.0 4.5% | 47,267.0 (1.6%) | 44,033.0 (6.8%) | 42,237.0 (4.1%) | 39,498.0 (6.5%) | 39,807.0 0.8% | 40,122.0 0.8% | 42,294.0 5.4% | 46,840.0 10.7% | 41,518.0 (11.4%) | 48,704.0 17.3% | 59,283.0 21.7% | 60,115.0 1.4% |
| Cost of Goods Sold (COGS) | 4,959.8 | 5,149.6 | 6,001.1 | 6,140.7 | 5,582.5 | 9,018.9 | 18,396.0 | 16,871.0 | 16,446.0 | 16,954.0 | 16,768.0 | 14,934.0 | 13,891.0 | 12,775.0 | 13,509.0 | 14,112.0 | 13,618.0 | 13,626.0 | 17,411.0 | 16,126.0 |
% margin | 17,978.8 78.4% | 16,862.3 76.6% | 16,634.9 73.5% | 18,057.0 74.6% | 18,267.8 76.6% | 18,409.4 67.1% | 27,591.0 60.0% | 31,176.0 64.9% | 30,821.0 65.2% | 27,079.0 61.5% | 25,469.0 60.3% | 24,564.0 62.2% | 25,916.0 65.1% | 27,347.0 68.2% | 28,785.0 68.1% | 32,728.0 69.9% | 27,900.0 67.2% | 35,078.0 72.0% | 41,872.0 70.6% | 43,989.0 73.2% |
| Operating Expenses | 11,356.5 | 11,003.5 | 12,948.3 | 12,439.5 | 12,182.3 | 14,388.2 | 24,236.0 | 22,200.0 | 20,944.0 | 19,414.0 | 18,786.0 | 17,017.0 | 16,956.0 | 19,812.0 | 19,854.0 | 20,487.0 | 22,352.0 | 21,879.0 | 23,590.0 | 40,912.0 |
| Research & Development Expenses (R&D) | 4,010.2 | 3,848.0 | 4,782.9 | 4,882.8 | 4,805.3 | 5,845.0 | 10,991.0 | 8,467.0 | 8,168.0 | 7,503.0 | 7,180.0 | 6,704.0 | 7,194.0 | 9,982.0 | 9,752.0 | 9,872.0 | 13,397.0 | 12,245.0 | 13,548.0 | 30,531.0 |
| Selling, General & Administrative Expenses (SG&A) | 7,346.3 | 7,155.5 | 8,165.4 | 7,556.7 | 7,377.0 | 8,543.2 | 13,245.0 | 13,733.0 | 12,776.0 | 11,911.0 | 11,606.0 | 10,313.0 | 9,762.0 | 9,830.0 | 10,102.0 | 10,615.0 | 8,955.0 | 9,634.0 | 10,042.0 | 10,504.0 |
% margin | 6,130.5 26.7% | 6,044.4 27.5% | 3,714.9 16.4% | 11,076.2 45.8% | 5,180.0 21.7% | (7,590.4) (27.7%) | 4,025.0 8.8% | 2,358.0 4.9% | 3,817.0 8.1% | 1,357.0 3.1% | 12,517.0 29.6% | 1,594.0 4.0% | 3,576.0 9.0% | 3,629.0 9.0% | 5,731.0 13.6% | 9,227.0 19.7% | 6,076.0 14.6% | 13,703.0 28.1% | 19,399.0 32.7% | 2,954.0 4.9% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 631.0 | 210.2 | 83.0 | 199.0 | 232.0 | 264.0 | 266.0 | 289.0 | 328.0 | 385.0 | 343.0 | 274.0 | 59.0 | 36.0 | 157.0 | 365.0 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 251.0 | 458.0 | 715.0 | 749.0 | 714.0 | 801.0 | 732.0 | 672.0 | 693.0 | 754.0 | 772.0 | 893.0 | 831.0 | 806.0 | 962.0 | 1,146.0 |
| Pre-tax Income | 7,974.5 | 7,363.9 | 6,221.4 | 3,370.7 | 9,807.8 | 15,291.8 | 1,653.0 | 7,334.0 | 9,232.0 | 5,545.0 | 17,283.0 | 5,401.0 | 7,499.0 | 6,747.0 | 8,701.0 | 11,464.0 | 8,791.0 | 13,879.0 | 16,444.0 | 1,889.0 |
% effective tax rate | 2,161.1 27.1% | 2,732.6 37.1% | 1,787.6 28.7% | 95.3 2.8% | 1,999.4 20.4% | 2,267.6 14.8% | 671.0 40.6% | 942.0 12.8% | 2,440.0 26.4% | 1,028.0 18.5% | 5,349.0 30.9% | 942.0 17.4% | 1,787.0 23.8% | 4,155.0 61.6% | 2,508.0 28.8% | 1,687.0 14.7% | 1,709.0 19.4% | 1,521.0 11.0% | 1,918.0 11.7% | 1,512.0 80.0% |
% margin | 5,813.4 25.3% | 4,631.3 21.0% | 4,433.8 19.6% | 3,275.4 13.5% | 7,808.4 32.7% | 12,901.3 47.0% | 861.0 1.9% | 6,272.0 13.1% | 6,661.0 14.1% | 4,404.0 10.0% | 11,920.0 28.2% | 4,442.0 11.2% | 5,691.0 14.3% | 2,568.0 6.4% | 6,220.0 14.7% | 9,843.0 21.0% | 7,067.0 17.0% | 13,049.0 26.8% | 14,519.0 24.5% | 365.0 0.6% |
| EPS | 2.63 | 2.11 | 2.04 | (1.04) | 3.65 | 4.15 | 0.28 | 2.06 | 2.20 | 1.50 | 4.20 | 1.60 | 2.07 | 0.95 | 2.40 | 3.84 | 2.79 | 5.16 | 5.73 | 0.14 |
| Diluted EPS | 2.62 | 2.10 | 2.03 | (1.04) | 3.63 | 4.15 | 0.28 | 2.02 | 2.16 | 1.47 | 4.07 | 1.56 | 2.04 | 0.93 | 2.32 | 3.82 | 2.78 | 5.14 | 5.71 | 0.14 |
% margin | 7,581.2 33.0% | 7,752.5 35.2% | 5,983.3 26.4% | 13,064.4 54.0% | 11,814.2 49.5% | 18,325.8 66.8% | 9,749.0 21.2% | 15,510.0 32.3% | 16,431.0 34.8% | 13,334.0 30.3% | 24,706.0 58.5% | 12,448.0 31.5% | 10,793.0 27.1% | 11,951.0 29.8% | 13,992.0 33.1% | 16,009.0 34.2% | 10,180.0 24.5% | 17,899.0 36.8% | 21,315.0 36.0% | 6,907.0 11.5% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Merck & Co., Inc.'s Net Debt to Free Cash Flow?
As of today, Microsoft Corp's last 12-month Net Debt to Free Cash Flow is (0.9x), based on the financial report for Dec 31, 2024 (Q4’2024). The average annual Net Debt to Free Cash Flow for Merck & Co., Inc. have been 1.9x over the past three years, and 2.3x over the past five years.
2) Is Merck & Co., Inc.'s Net Debt to Free Cash Flow Good?
As of today, Merck & Co., Inc.'s Net Debt to Free Cash Flow is (0.9x), which is lower than industry median of 1.3x. It indicates that Merck & Co., Inc.'s Net Debt to Free Cash Flow is Good.